Related references
Note: Only part of the references are listed.Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients
Allison L. M. Jordan et al.
MULTIPLE SCLEROSIS JOURNAL (2022)
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Edward Fox et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Rituximab treatment for multiple sclerosis
Benjamin V. Ineichen et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis
L. Scappaticcio et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2020)
Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis
D. Baker et al.
EUROPEAN JOURNAL OF NEUROLOGY (2020)
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
Robert T. Naismith et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
Gustavo Luna et al.
JAMA NEUROLOGY (2020)
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
Peter Alping et al.
ANNALS OF NEUROLOGY (2020)
Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosis
Russell Ouellette et al.
ANNALS OF NEUROLOGY (2020)
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study
Robert T. Naismith et al.
CNS DRUGS (2020)
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
Jeremy Chataway et al.
LANCET NEUROLOGY (2020)
MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice
Jaume Sastre-Garriga et al.
NATURE REVIEWS NEUROLOGY (2020)
Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis
Daniel M. Hartung et al.
NEUROLOGY (2020)
Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis
Andrew P. Robinson et al.
SCIENTIFIC REPORTS (2020)
Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden
Tine Iskov Kopp et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
Anna He et al.
LANCET NEUROLOGY (2020)
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
Ludwig Kappos et al.
JAMA NEUROLOGY (2020)
Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing -remitting multiple sclerosis
Andreas Muehler et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: A Review Article
Stanley Cohan et al.
BIOMEDICINES (2020)
Remyelination in multiple sclerosis: from basic science to clinical translation
Catherine Lubetzki et al.
LANCET NEUROLOGY (2020)
Aggressive multiple sclerosis (2): Treatment
Georgina Arrambide et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated Fas-Casp8-Bid-axis
Karl E. Carlstrom et al.
NATURE COMMUNICATIONS (2020)
Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate
Daniel Wynn et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis (vol 3, e124714, 2018)
Michael P. Pender et al.
JCI INSIGHT (2020)
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
Mark A. Agius et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
Mark A. Agius et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Initial Impairment and Recovery of Vision-Related Functioning in Participants With Acute Optic Neuritis From the RENEW Trial of Opicinumab
Jennifer Petrillo et al.
JOURNAL OF NEURO-OPHTHALMOLOGY (2019)
Dynamics of oligodendrocyte generation in multiple sclerosis
Maggie S. Y. Yeung et al.
NATURE (2019)
Altered human oligodendrocyte heterogeneity in multiple sclerosis
Sarah Jakel et al.
NATURE (2019)
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis
Katharine Harding et al.
JAMA NEUROLOGY (2019)
Out-of-pocket costs are on the rise for commonly prescribed neurologic medications
Brian C. Callaghan et al.
NEUROLOGY (2019)
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Xavier Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects
Luisa Klotz et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement
Pavan Bhargava et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
Maria Pia Sormani et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
Multiple sclerosis: clinical trial design 2019
Matteo Pardini et al.
CURRENT OPINION IN NEUROLOGY (2019)
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
Diego Cadavid et al.
LANCET NEUROLOGY (2019)
GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis
Edoardo Galli et al.
NATURE MEDICINE (2019)
pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis
David Kremer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Bruce A. C. Cree et al.
LANCET (2019)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
Jeffrey A. Cohen et al.
LANCET NEUROLOGY (2019)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
Giancarlo Comi et al.
LANCET NEUROLOGY (2019)
Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis
Lidia Stork et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis
Hans Lassmann
FRONTIERS IN IMMUNOLOGY (2019)
IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis
Christina Lueckel et al.
NATURE COMMUNICATIONS (2019)
VLA-2 blockade in vivo by vatelizumab induces CD4+FoxP3+ regulatory T cells
Johanna Breuer et al.
INTERNATIONAL IMMUNOLOGY (2019)
Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
Trygve Holmoy et al.
BMC RESEARCH NOTES (2019)
T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention
Jamie van Langelaar et al.
BRAIN (2018)
The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+T lymphocytes and B cells
Joana Machado-Santos et al.
BRAIN (2018)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Ludwig Kappos et al.
LANCET (2018)
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Raja Kapoor et al.
LANCET NEUROLOGY (2018)
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson et al.
LANCET NEUROLOGY (2018)
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Xavier Montalban et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Reassessing B cell contributions in multiple sclerosis
Rui Li et al.
NATURE IMMUNOLOGY (2018)
Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis
Jeremy Chataway et al.
NEUROLOGY (2018)
IL-1β enables CNS access to CCR2hi monocytes and the generation of pathogenic cells through GM-CSF released by CNS endothelial cells
Alexandre Pare et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Alemtuzumab as Treatment for Multiple Sclerosis
Serafeim Katsavos et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
Mathias Granqvist et al.
JAMA NEUROLOGY (2018)
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Xavier Montalban et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study
Julian Gold et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)
Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis
Ivan Jelcic et al.
CELL (2018)
Neurofilaments as biomarkers in neurological disorders
Michael Khalil et al.
NATURE REVIEWS NEUROLOGY (2018)
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis
Tanuja Chitnis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Deciding on the Best Multiple Sclerosis Therapy Tough Choices
Joseph R. Berger et al.
JAMA NEUROLOGY (2018)
Intrathecal treatment trial of rituximab in progressive MS An open-label phase 1b study
Joakim Bergman et al.
NEUROLOGY (2018)
Multiple sclerosis
Massimo Filippi et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging
Assunta Dal-Bianco et al.
ACTA NEUROPATHOLOGICA (2017)
Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study
Caryl J. Schwartzbach et al.
JOURNAL OF NEUROLOGY (2017)
ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis
Samia J. Khoury et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial
Karen Schreiber et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis
Tomas Olsson et al.
NATURE REVIEWS NEUROLOGY (2017)
ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis
Samia J. Khoury et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial
Karen Schreiber et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial
Ari J. Green et al.
LANCET (2017)
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial
Vincent Meininger et al.
LANCET NEUROLOGY (2017)
New insights into the burden and costs of multiple sclerosis in Europe
Gisela Kobelt et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis
Paolo A. Muraro et al.
NATURE REVIEWS NEUROLOGY (2017)
Alemtuzumab CARE-MS I 5-year follow-up Durable efficacy in the absence of continuous MS therapy
Eva Havrdova et al.
NEUROLOGY (2017)
Autologous hematopoietic stem cell transplantation in multiple sclerosis A meta-analysis
Maria Pia Sormani et al.
NEUROLOGY (2017)
Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012
Sarah Burkill et al.
NEUROLOGY (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis
L. M. Metz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
New insights into the burden and costs of multiple sclerosis in Europe
Gisela Kobelt et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Safety/tolerability of the anti-semaphorin 4D antibody VX15/2503 in a randomized phase 1 trial
Christopher LaGanke et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
In vivo characterization of cortical and white matter neuroaxonal pathology in early multiple sclerosis
Tobias Granberg et al.
BRAIN (2017)
Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients
Gijsbert P. van Nierop et al.
ACTA NEUROPATHOLOGICA (2017)
The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain
Lukas Haider et al.
BRAIN (2016)
Minocycline added to subcutaneous interferon-1a in multiple sclerosis: randomized RECYCLINE study
P. S. Sorensen et al.
EUROPEAN JOURNAL OF NEUROLOGY (2016)
Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study
Eva Havrdova et al.
JOURNAL OF NEUROLOGY (2016)
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Fred Lublin et al.
LANCET (2016)
Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial
Ludwig Kappos et al.
LANCET NEUROLOGY (2016)
A genetic basis for multiple sclerosis severity: Red herring or real?
Vilija G. Jokubaitis et al.
MOLECULAR AND CELLULAR PROBES (2016)
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
Douglas L. Arnold et al.
NEUROLOGY (2016)
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
Mika Komori et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Melanoma cell adhesion molecule-positive CD8 T lymphocytes mediate central nervous system inflammation
Catherine Larochelle et al.
ANNALS OF NEUROLOGY (2015)
Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque
Josa M. Frischer et al.
ANNALS OF NEUROLOGY (2015)
ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis
Robert C. Sergott et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2015)
Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies
Jesus Lovera et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2015)
Progressive multiple sclerosis 1 Pathological mechanisms in progressive multiple sclerosis
Don H. Mahad et al.
LANCET NEUROLOGY (2015)
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
L. Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis
Yonghao Cao et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Association of Cortical Lesion Burden on 7-T Magnetic Resonance Imaging With Cognition and Disability in Multiple Sclerosis
Daniel M. Harrison et al.
JAMA NEUROLOGY (2015)
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis A Randomized Clinical Trial
Jeffrey Cohen et al.
JAMA NEUROLOGY (2015)
GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis
Jerry S. Wolinsky et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Therapy-related acute leukaemia with mitoxantrone: Four years on, what is the risk and can it be limited?
Richard Ellis et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis
Cris S. Constantinescu et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
Anti-JC Virus Antibody Levels in Serum or Plasma Further Define Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Tatiana Plavina et al.
ANNALS OF NEUROLOGY (2014)
Cardiotoxicity of Mitoxantrone Treatment in a German Cohort of 639 Multiple Sclerosis Patients
Vinzenz Fleischer et al.
JOURNAL OF CLINICAL NEUROLOGY (2014)
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
T. L. Vollmer et al.
JOURNAL OF NEUROLOGY (2014)
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial
Thomas P. Leist et al.
LANCET NEUROLOGY (2014)
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
Christian Confavreux et al.
LANCET NEUROLOGY (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
Patrick Vermersch et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis
Feng Mei et al.
NATURE MEDICINE (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
Omar Khan et al.
ANNALS OF NEUROLOGY (2013)
The mechanism of action of glatiramer acetate in multiple sclerosis and beyond
Rina Aharoni
AUTOIMMUNITY REVIEWS (2013)
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
Maria Pia Sormani et al.
LANCET NEUROLOGY (2013)
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort
Tomas Olsson et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study
Christian Wolf et al.
PLOS ONE (2013)
Communication between pathogenic T cells and myeloid cells in neuroinflammatory disease
Laura Codarri et al.
TRENDS IN IMMUNOLOGY (2013)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor
LANCET NEUROLOGY (2012)
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial
David H. Miller et al.
LANCET NEUROLOGY (2012)
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Giancarlo Comi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Owain W. Howell et al.
BRAIN (2011)
A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and-23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis
Timothy L. Vollmer et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
S. Cook et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Paul O'Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2011)
A Gradient of Neuronal Loss and Meningeal Inflammation in Multiple Sclerosis
Roberta Magliozzi et al.
ANNALS OF NEUROLOGY (2010)
The changing demographic pattern of multiple sclerosis epidemiology
Nils Koch-Henriksen et al.
LANCET NEUROLOGY (2010)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
G. Comi et al.
LANCET (2009)
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis a phase I/II study. (vol 8, pg 244, 2009)
R. K. Burt et al.
LANCET NEUROLOGY (2009)
Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis
Bibiana Bielekova et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
Paul O'Connor et al.
LANCET NEUROLOGY (2009)
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study
Richard K. Burt et al.
LANCET NEUROLOGY (2009)
Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis
Hideki Garren et al.
ANNALS OF NEUROLOGY (2008)
Modulation of CCR2 in rheumatoid arthritis - A double-blind, randomized, placebo-controlled clinical trial
Clarissa E. Vergunst et al.
ARTHRITIS AND RHEUMATISM (2008)
Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies
Ralf A Linker et al.
Expert Review of Neurotherapeutics (2008)
Repeated subcutaneous injections of IL12/23 P40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study
Benjamin M. Segal et al.
LANCET NEUROLOGY (2008)
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol et al.
LANCET NEUROLOGY (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The origin and application of experimental autoimmune encephalomyelitis
Alan G. Baxter
NATURE REVIEWS IMMUNOLOGY (2007)
Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation
Hania Kebir et al.
NATURE MEDICINE (2007)
Extensive cortical remyelination in patients with chronic multiple sclerosis
Monika Albert et al.
BRAIN PATHOLOGY (2007)
Remyelination is extensive in a subset of multiple sclerosis patients
Peter Patrikios et al.
BRAIN (2006)
How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis
Lawrence Steinman et al.
ANNALS OF NEUROLOGY (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis
D Mahad et al.
BRAIN (2006)
Experimental allergic encephalomyelitis: A misleading model of multiple sclerosis
S Sriram et al.
ANNALS OF NEUROLOGY (2005)
Cortical demyelination and diffuse white matter injury in multiple sclerosis
A Kutzelnigg et al.
BRAIN (2005)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
The immune modulator FTY720 targets sphingosine 1-phosphate receptors
V Brinkmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Depletion of V beta 5.2/5.3 T cells with a humanized antibody in patients with multiple sclerosis
T Olsson et al.
EUROPEAN JOURNAL OF NEUROLOGY (2002)
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
B Bielekova et al.
NATURE MEDICINE (2000)
Linomide in the treatment of multiple sclerosis:: MRI results from prematurely terminated phase-III trials
IL Tan et al.
MULTIPLE SCLEROSIS (2000)
Share Paper
